Are some human lymphoblastoid cell lines established from leukemic tissues actually derived from normal leukocytes?
✍ Scribed by D. Belpomme; J. Minowada; G. E. Moore
- Publisher
- John Wiley and Sons
- Year
- 1972
- Tongue
- English
- Weight
- 567 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
In many laboratories, lymphoid cell lines have been initiated from the blood and hematopoietic tissues of patients with leukemia, lymphomas, or other malignant diseases, a n d from normal persons. A majority of human lymphoid cell lines have characteristics of normalcy. Even cell lines derived from leukemic blood may not represent leukemic cells. Before a lymphoid cell line is labeled "leukemic" or "malignant," some characteristics of malignancy should b e present, such as an abnormal chromosome constitution, production of abnormal immunoglobulin, high cloning efficiency, or growth in immunosuppressed heterologous hosts. ERMANENT LYMPHORLASTOID OR LYMPHOID P cell lines were established from Burkitt's tumor20 and leukemic bl00d3~ and the blood of normal persons40 between 1964 and 1966. Since then, numerous continuous cell lines have been grown in several laboratories from 57,eG and bone marrow,10,12J3 blood and bone tients with m o n o n u c l e o ~i s , l ~~~2 ~~3 ~~~ and from the lymph n0des33,35.48,~~,~4 and spleenl~~3j of patients without any detectable disease.
Permanent cell lines obtained by culturing leukemic blood do not necessarily possess malignant properties, in contrast to the preponderance of malignant characteristics of Burkitt cell lines. The purpose of these studies was clarification of the origin and characteristics of cell line5 obtained from leukemic blood that might have been derived from normal leukocytes present in the initial blood sample. lymphomas,52,5&jS leukemic blood8,"16,22.47,51, marrow from healthy s u b j e ~t s , 2 3 ~4 6 ~~~~5 ~ Pa-
DATA
Morphological appearance: Except in a very few cases, e.g., a cell line derived from the peripheral blood of a patient with mye-